Australia - English - Department of Health (Therapeutic Goods Administration)

aurobindo pharma australia pty ltd - candesartan cilexetil -

Australia - English - Department of Health (Therapeutic Goods Administration)

aurobindo pharma australia pty ltd - candesartan cilexetil -

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - hydrochlorothiazide, quantity: 25 mg; candesartan cilexetil, quantity: 32 mg - tablet - excipient ingredients: carrageenan; povidone; lactose monohydrate; magnesium stearate; croscarmellose sodium; iron oxide black; titanium dioxide; maize starch; iron oxide red - the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - hydrochlorothiazide, quantity: 12.5 mg; candesartan cilexetil, quantity: 32 mg - tablet, uncoated - excipient ingredients: hyprolose; magnesium stearate; maize starch; lactose monohydrate; carmellose calcium; macrogol 8000; iron oxide yellow - the treatment of hypertension. treatment should not be initiated with these fixed dose combinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - hydrochlorothiazide, quantity: 12.5 mg; candesartan cilexetil, quantity: 16 mg - tablet, uncoated - excipient ingredients: carmellose calcium; magnesium stearate; lactose monohydrate; macrogol 8000; hyprolose; maize starch; iron oxide red - the treatment of hypertension. treatment should not be initiated with these fixed dose combinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - candesartan cilexetil, quantity: 32 mg; hydrochlorothiazide, quantity: 25 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium stearate; maize starch; carmellose calcium; macrogol 8000; hyprolose; iron oxide red - the treatment of hypertension. treatment should not be initiated with these fixed dose combinations.

United States - English - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - candesartan cilexetil (unii: r85m2x0d68) (candesartan - unii:s8q36md2xx), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - candesartan cilexetil and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with candesartan cilexetil and hydrochlorothiazide. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint natio

United States - English - NLM (National Library of Medicine)

zydus lifesciences limited - candesartan cilexetil (unii: r85m2x0d68) (candesartan - unii:s8q36md2xx), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - candesartan cilexetil and hydrochlorothiazide tablets, usp are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with candesartan cilexetil and hydrochlorothiazide. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint

United States - English - NLM (National Library of Medicine)

solco healthcare llc - candesartan cilexetil (unii: r85m2x0d68) (candesartan - unii:s8q36md2xx), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - candesartan cilexetil and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with candesartan cilexetil and hydrochlorothiazide tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joi

United States - English - NLM (National Library of Medicine)

ani pharmaceuticals, inc. - candesartan cilexetil (unii: r85m2x0d68) (candesartan - unii:s8q36md2xx), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - candesartan cilexetil and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with candesartan cilexetil and hydrochlorothiazide tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’